» Articles » PMID: 9643624

Different Standards for Reporting ADRs to Herbal Remedies and Conventional OTC Medicines: Face-to-face Interviews with 515 Users of Herbal Remedies

Overview
Specialty Pharmacology
Date 1998 Jun 27
PMID 9643624
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To determine whether adverse drug reactions (ADRs) to herbal remedies would be reported differently from similar ADRs to conventional over-the-counter (OTC) medicines by herbal-remedy users.

Methods: Face-to-face interviews (using a structured questionnaire) with 515 users of herbal remedies were conducted in six pharmacy stores and six healthfood stores in the UK. The questionnaire focused on the likely course of action taken by herbal-remedy users after experiencing an ADR associated with a conventional OTC medicine and a herbal remedy.

Results: Following a 'serious' suspected ADR, 156 respondents (30.3%) would consult their GP irrespective of whether the ADR was associated with the use of a herbal remedy or a conventional OTC medicine, whereas 221 respondents (42.9%) would not consult their GP for a serious ADR associated with either type of preparation. One hundred and thirty-four respondents (26.0%) would consult their GP for a serious ADR to a conventional OTC medicine, but not for a similar ADR to a herbal remedy, whereas four respondents (0.8%) would consult their GP for a serious ADR to a herbal remedy, but not for a similar ADR to a conventional OTC medicine. Similar differences were found in attitudes towards reporting 'minor' suspected ADRs.

Conclusions: Consumers of herbal remedies would act differently with regard to reporting an ADR (serious or minor) to their GP depending on whether it was associated with a herbal remedy or a conventional OTC medicine. This has implications for herbal pharmacovigilance, particularly given the increasing use of OTC herbal remedies. The finding that a high proportion of respondents would not consult their GP or pharmacist following ADRs to conventional OTC medicines is also of concern.

Citing Articles

Pharmacovigilance systems for safety monitoring of herbal medicines: assessment of the national regulatory authority, manufacturers and marketing authorisation holders in Tanzania.

Mssusa A, Holst L, Maregesi S, Kagashe G J Pharm Policy Pract. 2025; 18(1):2438223.

PMID: 39776467 PMC: 11703424. DOI: 10.1080/20523211.2024.2438223.


Thai stakeholders' awareness and perceptions of the patient adverse event reporting system for herbal medicines: a qualitative study.

Worakunphanich W, Suwankesawong W, Youngkong S, Thavorncharoensap M, Anderson C, Toh L Int J Clin Pharm. 2023; 45(2):491-501.

PMID: 36745312 PMC: 9901401. DOI: 10.1007/s11096-022-01533-1.


Herbal supplements in Jordan: a cross-sectional survey of pharmacists' perspectives and knowledge.

Jalil B, Naser A, Prieto J, Heinrich M BMJ Open. 2022; 12(7):e057405.

PMID: 35896285 PMC: 9335029. DOI: 10.1136/bmjopen-2021-057405.


Community Pharmacists' Views and Experiences with ADR Reporting for Complementary Medicines: A Qualitative Study in New Zealand.

Barnes J, Butler R Drug Saf. 2020; 43(11):1157-1170.

PMID: 32975740 DOI: 10.1007/s40264-020-00980-x.


Role of Wight and Arn. in the treatment of chronic coronary artery disease from pharmacovigilance point of view.

Dwivedi S, Chopra D, Bhandari B Ayu. 2020; 40(2):104-108.

PMID: 32398910 PMC: 7210819. DOI: 10.4103/ayu.AYU_114_18.


References
1.
Fisher P, Ward A . Complementary medicine in Europe. BMJ. 1994; 309(6947):107-11. PMC: 2540528. DOI: 10.1136/bmj.309.6947.107. View

2.
Abbot N, White A, Ernst E . Complementary medicine. Nature. 1996; 381(6581):361. DOI: 10.1038/381361a0. View

3.
EISENBERG D, Kessler R, Foster C, Norlock F, Calkins D, Delbanco T . Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993; 328(4):246-52. DOI: 10.1056/NEJM199301283280406. View

4.
Smith C, Bennett P, PEARCE H, Harrison P, Reynolds D, Aronson J . Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol. 1996; 42(4):423-9. PMC: 2042689. DOI: 10.1046/j.1365-2125.1996.04376.x. View

5.
de Smet P . Health risks of herbal remedies. Drug Saf. 1995; 13(2):81-93. DOI: 10.2165/00002018-199513020-00003. View